Toll Like Receptor 8 (CD288 or TLR8) – Drugs in Development, 2021

Toll Like Receptor 8 (CD288 or TLR8) – Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 29 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 7, 1, 9 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Solid Tumor, Hepatitis B, Melanoma, Systemic Lupus Erythematosus, Autoimmune Disorders, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Triple-Negative Breast Cancer (TNBC), Bladder Cancer, Head And Neck Cancer, Metastatic Melanoma, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Adenoid Cystic Carcinoma (ACC), Arthritis, Colon Cancer, Coronavirus Disease 2019 (COVID-19), Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Fibrosis, Inflammation, Leukemia, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Mycosis Fungoides, Osteoarthritis, Peritoneal Cancer, Pneumonia, Prostate Cancer, Rheumatoid Arthritis, Sarcomas, Sicca Syndrome (Sjogren), Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer and Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease).

The latest report Toll Like Receptor 8 – Drugs in Development, 2021, outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)

– The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects

– The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Altimmune Inc

Ascendis Pharma AS

Bolt Biotherapeutics Inc

Bristol-Myers Squibb Co

Curebiotech Inc

Curevac NV

Dynavax Technologies Corp

Eisai Co Ltd

Galderma SA

Gilead Sciences Inc

IngenoVax LLC

Janus Biotherapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

Merck KGaA

Nektar Therapeutics

Novartis AG

Resolve Therapeutics LLC

Seven and Eight Biopharmaceuticals Corp

Shanghai De Novo Pharmatech Co Ltd

Shanghai Zhimeng Biopharma Inc

Silverback Therapeutics Inc

UroGen Pharma Ltd

Vaccex Inc

Table of Contents

Table of Contents

Introduction

Toll Like Receptor 8 (CD288 or TLR8) - Overview

Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment

Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development

Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles

Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products

Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Indications, 2021 (Contd..1)

Number of Products under Development by Indications, 2021 (Contd..2)

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Altimmune Inc, 2021

Pipeline by Ascendis Pharma AS, 2021

Pipeline by Bolt Biotherapeutics Inc, 2021

Pipeline by Bristol-Myers Squibb Co, 2021

Pipeline by Curebiotech Inc, 2021

Pipeline by Curevac NV, 2021

Pipeline by Dynavax Technologies Corp, 2021

Pipeline by Eisai Co Ltd, 2021

Pipeline by Galderma SA, 2021

Pipeline by Gilead Sciences Inc, 2021

Pipeline by IngenoVax LLC, 2021

Pipeline by Janus Biotherapeutics Inc, 2021

Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021

Pipeline by Merck KGaA, 2021

Pipeline by Nektar Therapeutics, 2021

Pipeline by Novartis AG, 2021

Pipeline by Resolve Therapeutics LLC, 2021

Pipeline by Seven and Eight Biopharmaceuticals Corp, 2021

Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2021

Pipeline by Shanghai Zhimeng Biopharma Inc, 2021

Pipeline by Silverback Therapeutics Inc, 2021

Pipeline by UroGen Pharma Ltd, 2021

Pipeline by Vaccex Inc, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Dormant Products, 2021 (Contd..2)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports